ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 35 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The firm is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Follow-Up Questions
What is ESSA Pharma Inc (EPIX)'s P/E Ratio?
The P/E ratio of ESSA Pharma Inc is N/A
Who is the CEO of ESSA Pharma Inc?
Dr. David Parkinson is the President of ESSA Pharma Inc, joining the firm since 2015.
What is the price performance of EPIX stock?
The current price of EPIX is 0.2144, it has increased 2.15% in the last trading day.
What are the primary business themes or industries for ESSA Pharma Inc?
ESSA Pharma Inc belongs to Biotechnology industry and the sector is Health Care
What is ESSA Pharma Inc market cap?
ESSA Pharma Inc's current market cap is $10.1
Is ESSA Pharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for ESSA Pharma Inc, including 0 strong buy, 0 buy, 4 hold, 1 sell, and 0 strong sell
